ANI Pharmaceuticals Inc ANIP
ANI Pharmaceuticals Inc (Nasdaq: ANIP) is an immunology/inflammation specialty pharmaceutical company.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Purified Cortrophin Gel | chronic autoimmune disorders, nephrotic syndrome, acute gouty arthritis flares | protein/peptide | Approved |
| ILUVIEN (fluocinolone acetonide intravitreal implant) | diabetic macular edema; chronic non-infectious uveitis of the posterior segment | small molecule | Approved |
| YUTIQ (fluocinolone acetonide intravitreal implant) | non-infectious uveitis of the posterior segment | small molecule | Approved |
| Branded portfolio (Atacand, Arimidex, Casodex, Inderal LA/XL, Lithobid, Vancocin, etc.) | various | small molecule | Approved |
| Generics portfolio (>120 products, ANDA pipeline) | various | small molecule | Approved |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other approved immunology/inflammation companies
- Alvotech ALVO
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.